Cell Death and Targeted Cancer Therapies

103.2K

views

118

authors

16

articles

Editorial

06 July 2022

Editorial: Cell Death and Targeted Cancer Therapies

Tugba Bagci-Onder

,

Ozgur Kutuk

,

Triona Ni Chonghaile

and

Uwe Knippschild

2,521 views

0 citations

Editors

4

Sabancı University

Triona Ni Chonghaile

Royal College of Surgeons in Ireland

Tugba Bagci-Onder

Koç University

Uwe Knippschild

University of Ulm

Impact

About

Commitment of cells to programmed cell death via the mitochondrial pathway of apoptosis is governed by the BCL-2 protein family, comprising anti- and proapoptotic BCL-2 proteins. Of note, BCL2 family of proteins have been shown to play important roles in tumorigenesis as well as in the response of cancers to conventional chemotherapies and targeted therapies, including kinase inhibitors and BH3 mimetics. Nevertheless, our understanding of the precise mechanisms of apoptotic signaling networks in response to targeted therapies continue to evolve.

Resistance to therapy poses a prominent problem for the successful treatment of cancer, and there is a vast flow of information emerging in the field of drug resistance to cancer. Furthermore, improved clinical models, in particular patient-derived xenografts, and high-throughput screens, are providing in-depth understanding of how cancer cells evolve to resist treatment.

Specific subtopics will include, but are not limited to:
• Cell death signaling in targeted cancer therapies
• Mechanisms of resistance in targeted cancer therapies
• Cancer models and biomarkers for predicting cell death response in targeted cancer therapies
• Tumor microenvironment and response to targeted cancer therapies
• Non-apoptotic cell death signaling in targeted cancer therapies

Commitment of cells to programmed cell death via the mitochondrial pathway of apoptosis is governed by the BCL-2 protein family, comprising anti- and proapoptotic BCL-2 proteins. Of note, BCL2 family of proteins have been shown to play important roles in tumorigenesis as well as in the response of cancers to conventional chemotherapies and targeted therapies, including kinase inhibitors and BH3 mimetics. Nevertheless, our understanding of the precise mechanisms of apoptotic signaling networks in response to targeted therapies continue to evolve.

Resistance to therapy poses a prominent problem for the successful treatment of cancer, and there is a vast flow of information emerging in the field of drug resistance to cancer. Furthermore, improved clinical models, in particular patient-derived xenografts, and high-throughput screens, are providing in-depth understanding of how cancer cells evolve to resist treatment.

Specific subtopics will include, but are not limited to:
• Cell death signaling in targeted cancer therapies
• Mechanisms of resistance in targeted cancer therapies
• Cancer models and biomarkers for predicting cell death response in targeted cancer therapies
• Tumor microenvironment and response to targeted cancer therapies
• Non-apoptotic cell death signaling in targeted cancer therapies

Download ebook

Share

Editors

Sabancı University

Triona Ni Chonghaile

Royal College of Surgeons in Ireland

Tugba Bagci-Onder

Koç University

Uwe Knippschild

University of Ulm

Impact

103,164 Total views

71,468 Article views

30,076 Article downloads

1,620 Topic views

Published In

Journal Thumbnail

Frontiers in Cell and Developmental Biology

Cell Death and Survival

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic